We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton or kDa, purified botulinum toxin type A formulation indicated for the t... Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton or kDa, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. Show more
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial...
The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appearance of moderate to severe glabellar lines presented at the 2023...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following...
Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of $14.07 per share, which is equal...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.84 | 16.0558464223 | 11.46 | 13.54 | 11.31 | 767398 | 12.25180528 | CS |
4 | -0.11 | -0.820283370619 | 13.41 | 13.54 | 11.07 | 505956 | 12.19875508 | CS |
12 | -0.16 | -1.18870728083 | 13.46 | 15.4325 | 11.07 | 597734 | 13.47553826 | CS |
26 | 5.36 | 67.5062972292 | 7.94 | 15.4325 | 7.74 | 668307 | 11.59077615 | CS |
52 | 4.93 | 58.9008363202 | 8.37 | 15.4325 | 7.07 | 628682 | 10.2693916 | CS |
156 | 4.17 | 45.6736035049 | 9.13 | 15.4325 | 5.061 | 543130 | 9.77360131 | CS |
260 | -10.43 | -43.9528023599 | 23.73 | 25.34 | 2.85 | 650060 | 9.59891552 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions